# Royalty Pharma plc (RPRX) FY2025 Q1 Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-05-08, accession number 0001802768-25-000027
- Page: https://plicit.ai/financials/rprx/fy2025-q1-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2025-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 17,608,256,000 US dollars
- **Current assets**: 1,843,243,000 US dollars
- **Non-current assets**: 15,765,013,000 US dollars
- **Liabilities**: 7,819,599,000 US dollars
- **Current liabilities**: 1,182,852,000 US dollars
- **Non-current liabilities**: 6,636,747,000 US dollars
- **Equity**: 9,788,657,000 US dollars
- **Noncontrolling interest**: 3,100,010,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Cash and cash equivalents**: 1,087,720,000 US dollars
- **Financial royalty assets**: 716,559,000 US dollars
- **Other royalty income receivable**: 23,785,000 US dollars
- **Available for sale debt securities**: 12,100,000 US dollars
- **Other current assets**: 3,079,000 US dollars
- **Financial royalty assets, net**: 15,032,015,000 US dollars
- **Equity method investments**: 336,208,000 US dollars
- **Available for sale debt securities**: 219,000,000 US dollars
- **Equity securities**: 141,083,000 US dollars
- **Other assets**: 36,707,000 US dollars
- **Current portion of long-term debt**: 998,605,000 US dollars
- **Distributions payable to non-controlling interests**: 108,796,000 US dollars
- **Accounts payable and accrued expenses**: 37,630,000 US dollars
- **Interest payable**: 19,221,000 US dollars
- **Other current liabilities**: 18,600,000 US dollars
- **Long-term debt**: 6,618,847,000 US dollars
- **Other liabilities**: 17,900,000 US dollars
- **Additional paid-in capital**: 4,210,531,000 US dollars
- **Retained earnings**: 2,480,664,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 43,000 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2025–394,513 and 2024–392,255**: 0 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Non-controlling interests**: 3,100,010,000 US dollars
- **Treasury interests**: negative 2,654,000 US dollars
- **Gross equity (calculated)**: 9,791,311,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.